Eisai SWOT Analysis, USP & Competitors

Posted in Pharmaceuticals and Healthcare, Total Reads: 1243
Advertisements

SWOT Analysis of Eisai with USP, Competition, STP (Segmentation, Targeting, Positioning) - Marketing Analysis

Eisai

Parent Company

Eisai

Category

Pharmaceutical

Sector

Healthcare

Tagline/ Slogan

Striving to be human healthcare company

USP

Its research based human healthcare ompany

STP

Segment

CNS, oncology, rheumatism, gastrointestinal diseases

Target Group

Healthcare professionals & doctors offering solutions in these segments

Positioning

They give first thought to the patients & their families and aim to increase the benefits provided by healthcare

SWOT Analysis

Strengths

1. Their blockbuster drug Aricept is major drug in Alzheimer’s disease

2. Eisai has identified multiple pathways to offer treatment to cancer patients

3. Strong product pipeline

4. Majority of drugs in maturing stage

5. Over 11,560 well trained employees

Weaknesses

1. Limited presence in emerging market

2. Limited number of bestseller drugs.

3. Patent expiration in U.S has adverse affect on sales

Opportunities

1. They can increase their presence in oncology segment via strategic acquisition

2. Increasing prevalence of chronic diseases such as Alzheimer’s disease

3. increasing awareness about healthcare solutions

Threats

1.  Growth rate in mature pharmaceutical market is decreasing

2.  Natural disasters in Japan

3.  Economic slowdown which reduces average spend on healthcare

Competition

Competitors

1. Takeda pharmaceutical

2. Astrazeneca PLC

3. Astellas pharmaceutical

4. Teva Pharmaceuticals



Advertisements



Looking for More Brands? Search BrandGuide

Edit the Brand or Add a New One : Contribute to BrandGuide

The brandnames and other brand information used in the brandguide section are properties of their respective companies. The companies are not associated with MBASkool in any way. The brand names are used purely for educational/academic purpose only.
Utmost Care has been taken in the analysis of the brands. However, if you find any ambiguity kindly help us improve.